The preclinical work on CD47, which binds SIRPα to deliver a 'don't eat me signal', was very compelling. But as a druggable target it's had a bumpy ride in clinical development.

'Pfizer executives were bullish during a second quarter earnings call Thursday that its two CD47 meds would not face the same setbacks seen from rivals Gilead and others. As a result, the New York pharma is staying the course.'
(HT Michael Tomasson)
#Immunology #immunotherapy #InnateImmunity

https://www.fiercebiotech.com/biotech/pfizer-undeterred-cd47-plans-competitors-face-pitfalls